Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 12/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 10/20 | 0.52 |
| ▸ | TSHR | P16473 | 6/20 | 0.52 |
| ▸ | USP2 | O75604 | 5/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16815697 | 0.92 | CYP1A2 (0.50) | CYP1A2CYP3A4CYP2D6ALDH1A1CYP2C19 | |
| SCHEMBL18342623 | 0.87 | KMT2A (0.46) | CYP1A2CYP3A4CYP2D6ALDH1A1CYP2C19 | |
| SCHEMBL20742511 | 0.87 | KMT2A (0.46) | CYP1A2CYP3A4CYP2D6ALDH1A1CYP2C19 | |
| SCHEMBL26993359 | 0.86 | CYP1A2 (0.60) | CYP1A2CYP3A4CYP2D6ALDH1A1CYP2C19 | |
| SCHEMBL16815681 | 0.85 | KMT2A (0.49) | CYP1A2CYP3A4CYP2D6ALDH1A1CYP2C19 | |
| SCHEMBL18342624 | 0.85 | KMT2A (0.44) | CYP1A2CYP3A4CYP2D6ALDH1A1CYP2C19 | |
| SCHEMBL26985853 | 0.84 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2D6ALDH1A1CYP2C19 | |
| SCHEMBL20742372 | 0.82 | KMT2A (0.49) | CYP1A2CYP3A4CYP2D6ALDH1A1CYP2C19 | |
| SCHEMBL16815687 | 0.82 | MAPT (0.52) | CYP1A2CYP3A4CYP2D6ALDH1A1TSHR | |
| SCHEMBL27346672 | 0.79 | CYP1A2 (0.67) | CYP1A2CYP3A4CYP2D6ALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250092062-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230183261-A1 | Macrocyclic MCL-1 Inhibitors and Methods of Use | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20220259226-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2022-08-18 | — | — | US | disclosed |
| EP-3988555-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20210292339-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2021-09-23 | — | — | US | disclosed |
| CN-108137497-B | Bicyclic derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2021-06-15 | — | — | CN | disclosed |
| CN-112739343-A | Macrocyclic MCL-1 inhibitors and methods of use | 艾伯维公司 | 2021-04-30 | — | — | CN | disclosed |
| US-20170216293-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2017-08-03 | — | — | US | disclosed |
| WO-2017125224-A1 | NEW AMMONIUM DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2017-07-27 | — | — | WO | disclosed |
| US-9670227-B2 | Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2017-06-06 | — | — | US | disclosed |
| WO-2016207225-A1 | NEW HYDROXYESTER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016207226-A1 | NEW AMINOACID DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016207217-A1 | NEW BICYCLIC DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2016-12-29 | — | — | WO | disclosed |
| EP-2886545-B1 | New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015097123-A1 | NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2015-07-02 | — | — | WO | disclosed |
| US-20150175623-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2015-06-25 | — | — | US | disclosed |
| EP-2886545-A1 | New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2015-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216293-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TYMS, TYMP, TPX2 | CYP1A2 230/4885CYP3A4 672/4885CYP2D6 319/4885 |
| US-20210292339-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | CYP1A2 2467/4885CYP3A4 3250/4885CYP2D6 1426/4885 |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | CYP1A2 2446/4885CYP3A4 3215/4885CYP2D6 1413/4885 |
| US-20230183261-A1 | Macrocyclic MCL-1 Inhibitors and Methods of Use | MCL1, BCL2A1, BCL2L10 | CYP1A2 2446/4885CYP3A4 3215/4885CYP2D6 1413/4885 |
| US-20250092062-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | CYP1A2 2446/4885CYP3A4 3215/4885CYP2D6 1413/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | CYP1A2 2446/4885CYP3A4 3215/4885CYP2D6 1413/4885 |
| US-20150175623-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TYMS, TYMP, TPX2 | CYP1A2 230/4885CYP3A4 672/4885CYP2D6 319/4885 |
| US-20220259226-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | CYP1A2 2467/4885CYP3A4 3250/4885CYP2D6 1426/4885 |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | CYP1A2 2446/4885CYP3A4 3215/4885CYP2D6 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.